MST-168
/ Mabsoft Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 13, 2026
Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors
(clinicaltrials.gov)
- P1 | N=420 | Not yet recruiting | Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd.
New P1 trial • Oncology • Solid Tumor
October 15, 2026
Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors
(clinicaltrials.gov)
- P1 | N=420 | Recruiting | Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2026 ➔ Nov 2026
Enrollment open • Trial initiation date • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1